Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 22973169)

1.

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.

Olsen IH, Sørensen JB, Federspiel B, Kjaer A, Hansen CP, Knigge U, Langer SW.

ScientificWorldJournal. 2012;2012:170496. doi: 10.1100/2012/170496. Epub 2012 Aug 22.

2.

Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.

Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K.

Cancer. 2011 Oct 15;117(20):4617-22. doi: 10.1002/cncr.26124. Epub 2011 Mar 31.

3.

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.

Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA.

Cancer Chemother Pharmacol. 2013 Mar;71(3):663-70. doi: 10.1007/s00280-012-2055-z. Epub 2013 Jan 31.

PMID:
23370660
4.

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS.

J Clin Oncol. 2006 Jan 20;24(3):401-6.

5.

Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.

Sipos L, Vitanovics D, Afra D.

Ideggyogy Sz. 2004 Nov 20;57(11-12):394-9.

PMID:
15662767
6.

Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.

Claringbold PG, Price RA, Turner JH.

Cancer Biother Radiopharm. 2012 Nov;27(9):561-9. doi: 10.1089/cbr.2012.1276. Epub 2012 Oct 18.

PMID:
23078020
7.

Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.

Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, Delfini R.

Tumori. 2007 May-Jun;93(3):248-56.

8.

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS.

Clin Cancer Res. 2009 Jan 1;15(1):338-45. doi: 10.1158/1078-0432.CCR-08-1476.

9.

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L.

Cancer. 2011 Jan 15;117(2):268-75. doi: 10.1002/cncr.25425. Epub 2010 Sep 7.

10.

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.

Chan JA, Blaszkowsky L, Stuart K, Zhu AX, Allen J, Wadlow R, Ryan DP, Meyerhardt J, Gonzalez M, Regan E, Zheng H, Kulke MH.

Cancer. 2013 Sep 1;119(17):3212-8. doi: 10.1002/cncr.28142. Epub 2013 Jun 3.

11.

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH.

J Clin Oncol. 2012 Aug 20;30(24):2963-8. doi: 10.1200/JCO.2011.40.3147. Epub 2012 Jul 9.

12.

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B.

Clin Cancer Res. 2007 May 15;13(10):2986-91.

13.

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR.

Cancer. 2003 Dec 15;98(12):2693-9.

14.

Extended-schedule dose-dense temozolomide in refractory gliomas.

Berrocal A, Perez Segura P, Gil M, Balaña C, Garcia Lopez J, Yaya R, Rodríguez J, Reynes G, Gallego O, Iglesias L; GENOM Cooperative Group.

J Neurooncol. 2010 Feb;96(3):417-22. doi: 10.1007/s11060-009-9980-7. Epub 2009 Aug 8.

15.
16.

[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].

Frick S, Lischner S, Rosien F, Haacke TC, Schäfer F, Christophers E, Hauschild A.

Hautarzt. 2002 Oct;53(10):659-65. German.

PMID:
12297947
17.

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S.

Ann Oncol. 2001 Feb;12(2):259-66.

18.

Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide.

Paulsen F, Hoffmann W, Becker G, Belka C, Weinmann M, Classen J, Kortmann RD, Bamberg M.

J Cancer Res Clin Oncol. 1999 Jul;125(7):411-8.

PMID:
10394962
19.

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE.

J Clin Oncol. 2009 Aug 10;27(23):3861-7. doi: 10.1200/JCO.2008.20.7944. Epub 2009 Jun 8.

20.

Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.

Makino K, Nakamura H, Hide T, Kuratsu J.

J Neurooncol. 2012 Jan;106(1):155-60. doi: 10.1007/s11060-011-0652-z. Epub 2011 Jul 1.

PMID:
21720808
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk